Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles
Cervical cancer remains a global health burden despite the introduction of highly effective vaccines for the prophylaxis of causative human papillomavirus infection (HPV). Current efforts to eradicate cervical cancer focus on the development of broadly protective, cost-effective approaches. HPV mino...
Saved in:
| Published in | Frontiers in immunology Vol. 11; p. 606569 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
04.12.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Cervical cancer remains a global health burden despite the introduction of highly effective vaccines for the prophylaxis of causative human papillomavirus infection (HPV). Current efforts to eradicate cervical cancer focus on the development of broadly protective, cost-effective approaches. HPV minor capsid protein L2 is being recognized as a promising alternative to the major capsid protein L1 because of its ability to induce responses against a wider range of different HPV types. However, a major limitation of L2 as a source of cross-neutralizing epitopes is its lower immunogenicity compared to L1 when assembled into VLPs. Various approaches have been proposed to overcome this limitation, we developed and tested ferritin-based bio-nanoparticles displaying tandemly repeated L2 epitopes from eight different HPV types grafted onto the surface of
thioredoxin (Pf Trx). Genetic fusion of the Pf Trx-L2(8x) module to
ferritin (Pf Fe) did not interfere with ferritin self-assembly into an octahedral structure composed by 24 protomers. In guinea pigs and mice, the ferritin super-scaffolded, L2 antigen induced a broadly neutralizing antibody response covering 14 oncogenic and two non-oncogenic HPV types. Immune-responsiveness lasted for at least one year and the resulting antibodies also conferred protection in a cervico-vaginal mouse model of HPV infection. Given the broad organism distribution of thioredoxin and ferritin, we also verified the lack of cross-reactivity of the antibodies elicited against the scaffolds with human thioredoxin or ferritin. Altogether, the results of this study point to
ferritin nanoparticles as a robust platform for the construction of peptide-epitope-based HPV vaccines. |
|---|---|
| AbstractList | Cervical cancer remains a global health burden despite the introduction of highly effective vaccines for the prophylaxis of causative human papillomavirus infection (HPV). Current efforts to eradicate cervical cancer focus on the development of broadly protective, cost-effective approaches. HPV minor capsid protein L2 is being recognized as a promising alternative to the major capsid protein L1 because of its ability to induce responses against a wider range of different HPV types. However, a major limitation of L2 as a source of cross-neutralizing epitopes is its lower immunogenicity compared to L1 when assembled into VLPs. Various approaches have been proposed to overcome this limitation, we developed and tested ferritin-based bio-nanoparticles displaying tandemly repeated L2 epitopes from eight different HPV types grafted onto the surface of Pyrococcus furiosus thioredoxin (Pf Trx). Genetic fusion of the Pf Trx-L2(8x) module to P. furiosus ferritin (Pf Fe) did not interfere with ferritin self-assembly into an octahedral structure composed by 24 protomers. In guinea pigs and mice, the ferritin super-scaffolded, L2 antigen induced a broadly neutralizing antibody response covering 14 oncogenic and two non-oncogenic HPV types. Immune-responsiveness lasted for at least one year and the resulting antibodies also conferred protection in a cervico-vaginal mouse model of HPV infection. Given the broad organism distribution of thioredoxin and ferritin, we also verified the lack of cross-reactivity of the antibodies elicited against the scaffolds with human thioredoxin or ferritin. Altogether, the results of this study point to P. furiosus ferritin nanoparticles as a robust platform for the construction of peptide-epitope-based HPV vaccines. Cervical cancer remains a global health burden despite the introduction of highly effective vaccines for the prophylaxis of causative human papillomavirus infection (HPV). Current efforts to eradicate cervical cancer focus on the development of broadly protective, cost-effective approaches. HPV minor capsid protein L2 is being recognized as a promising alternative to the major capsid protein L1 because of its ability to induce responses against a wider range of different HPV types. However, a major limitation of L2 as a source of cross-neutralizing epitopes is its lower immunogenicity compared to L1 when assembled into VLPs. Various approaches have been proposed to overcome this limitation, we developed and tested ferritin-based bio-nanoparticles displaying tandemly repeated L2 epitopes from eight different HPV types grafted onto the surface of Pyrococcus furiosus thioredoxin (Pf Trx). Genetic fusion of the Pf Trx-L2(8x) module to P. furiosus ferritin (Pf Fe) did not interfere with ferritin self-assembly into an octahedral structure composed by 24 protomers. In guinea pigs and mice, the ferritin super-scaffolded, L2 antigen induced a broadly neutralizing antibody response covering 14 oncogenic and two non-oncogenic HPV types. Immune-responsiveness lasted for at least one year and the resulting antibodies also conferred protection in a cervico-vaginal mouse model of HPV infection. Given the broad organism distribution of thioredoxin and ferritin, we also verified the lack of cross-reactivity of the antibodies elicited against the scaffolds with human thioredoxin or ferritin. Altogether, the results of this study point to P. furiosus ferritin nanoparticles as a robust platform for the construction of peptide-epitope-based HPV vaccines. Cervical cancer remains a global health burden despite the introduction of highly effective vaccines for the prophylaxis of causative human papillomavirus infection (HPV). Current efforts to eradicate cervical cancer focus on the development of broadly protective, cost-effective approaches. HPV minor capsid protein L2 is being recognized as a promising alternative to the major capsid protein L1 because of its ability to induce responses against a wider range of different HPV types. However, a major limitation of L2 as a source of cross-neutralizing epitopes is its lower immunogenicity compared to L1 when assembled into VLPs. Various approaches have been proposed to overcome this limitation, we developed and tested ferritin-based bio-nanoparticles displaying tandemly repeated L2 epitopes from eight different HPV types grafted onto the surface of Pyrococcus furiosus thioredoxin (Pf Trx). Genetic fusion of the Pf Trx-L2(8x) module to P. furiosus ferritin (Pf Fe) did not interfere with ferritin self-assembly into an octahedral structure composed by 24 protomers. In guinea pigs and mice, the ferritin super-scaffolded, L2 antigen induced a broadly neutralizing antibody response covering 14 oncogenic and two non-oncogenic HPV types. Immune-responsiveness lasted for at least one year and the resulting antibodies also conferred protection in a cervico-vaginal mouse model of HPV infection. Given the broad organism distribution of thioredoxin and ferritin, we also verified the lack of cross-reactivity of the antibodies elicited against the scaffolds with human thioredoxin or ferritin. Altogether, the results of this study point to P. furiosus ferritin nanoparticles as a robust platform for the construction of peptide-epitope-based HPV vaccines.Cervical cancer remains a global health burden despite the introduction of highly effective vaccines for the prophylaxis of causative human papillomavirus infection (HPV). Current efforts to eradicate cervical cancer focus on the development of broadly protective, cost-effective approaches. HPV minor capsid protein L2 is being recognized as a promising alternative to the major capsid protein L1 because of its ability to induce responses against a wider range of different HPV types. However, a major limitation of L2 as a source of cross-neutralizing epitopes is its lower immunogenicity compared to L1 when assembled into VLPs. Various approaches have been proposed to overcome this limitation, we developed and tested ferritin-based bio-nanoparticles displaying tandemly repeated L2 epitopes from eight different HPV types grafted onto the surface of Pyrococcus furiosus thioredoxin (Pf Trx). Genetic fusion of the Pf Trx-L2(8x) module to P. furiosus ferritin (Pf Fe) did not interfere with ferritin self-assembly into an octahedral structure composed by 24 protomers. In guinea pigs and mice, the ferritin super-scaffolded, L2 antigen induced a broadly neutralizing antibody response covering 14 oncogenic and two non-oncogenic HPV types. Immune-responsiveness lasted for at least one year and the resulting antibodies also conferred protection in a cervico-vaginal mouse model of HPV infection. Given the broad organism distribution of thioredoxin and ferritin, we also verified the lack of cross-reactivity of the antibodies elicited against the scaffolds with human thioredoxin or ferritin. Altogether, the results of this study point to P. furiosus ferritin nanoparticles as a robust platform for the construction of peptide-epitope-based HPV vaccines. Cervical cancer remains a global health burden despite the introduction of highly effective vaccines for the prophylaxis of causative human papillomavirus infection (HPV). Current efforts to eradicate cervical cancer focus on the development of broadly protective, cost-effective approaches. HPV minor capsid protein L2 is being recognized as a promising alternative to the major capsid protein L1 because of its ability to induce responses against a wider range of different HPV types. However, a major limitation of L2 as a source of cross-neutralizing epitopes is its lower immunogenicity compared to L1 when assembled into VLPs. Various approaches have been proposed to overcome this limitation, we developed and tested ferritin-based bio-nanoparticles displaying tandemly repeated L2 epitopes from eight different HPV types grafted onto the surface of thioredoxin (Pf Trx). Genetic fusion of the Pf Trx-L2(8x) module to ferritin (Pf Fe) did not interfere with ferritin self-assembly into an octahedral structure composed by 24 protomers. In guinea pigs and mice, the ferritin super-scaffolded, L2 antigen induced a broadly neutralizing antibody response covering 14 oncogenic and two non-oncogenic HPV types. Immune-responsiveness lasted for at least one year and the resulting antibodies also conferred protection in a cervico-vaginal mouse model of HPV infection. Given the broad organism distribution of thioredoxin and ferritin, we also verified the lack of cross-reactivity of the antibodies elicited against the scaffolds with human thioredoxin or ferritin. Altogether, the results of this study point to ferritin nanoparticles as a robust platform for the construction of peptide-epitope-based HPV vaccines. |
| Author | Ottonello, Simone Spagnoli, Gloria Mariz, Filipe C Zhao, Xueer Yang, Fan Müller, Martin |
| AuthorAffiliation | 1 Research Group Tumorvirus-Specific Vaccination Strategies, Research Program Infection Inflammation & Cancer, German Cancer Research Center , Heidelberg , Germany 2 Department of Chemical Life Sciences and Environmental Sustainability, University of Parma , Parma , Italy |
| AuthorAffiliation_xml | – name: 1 Research Group Tumorvirus-Specific Vaccination Strategies, Research Program Infection Inflammation & Cancer, German Cancer Research Center , Heidelberg , Germany – name: 2 Department of Chemical Life Sciences and Environmental Sustainability, University of Parma , Parma , Italy |
| Author_xml | – sequence: 1 givenname: Fan surname: Yang fullname: Yang, Fan organization: Research Group Tumorvirus-Specific Vaccination Strategies, Research Program Infection Inflammation & Cancer, German Cancer Research Center, Heidelberg, Germany – sequence: 2 givenname: Filipe C surname: Mariz fullname: Mariz, Filipe C organization: Research Group Tumorvirus-Specific Vaccination Strategies, Research Program Infection Inflammation & Cancer, German Cancer Research Center, Heidelberg, Germany – sequence: 3 givenname: Xueer surname: Zhao fullname: Zhao, Xueer organization: Research Group Tumorvirus-Specific Vaccination Strategies, Research Program Infection Inflammation & Cancer, German Cancer Research Center, Heidelberg, Germany – sequence: 4 givenname: Gloria surname: Spagnoli fullname: Spagnoli, Gloria organization: Department of Chemical Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy – sequence: 5 givenname: Simone surname: Ottonello fullname: Ottonello, Simone organization: Department of Chemical Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy – sequence: 6 givenname: Martin surname: Müller fullname: Müller, Martin organization: Research Group Tumorvirus-Specific Vaccination Strategies, Research Program Infection Inflammation & Cancer, German Cancer Research Center, Heidelberg, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33343580$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVks1u1DAUhSNUREvpA7BBXrKZwX-xkw1SW_VnpKGtEKytG-dmcJXYwXYqDc_EQ5LplKr15lr2Od-9ss_74sAHj0XxkdGlEFX9pXPDMC055XSpqCpV_aY4YkrJheBcHrzYHxYnKd3TeclaCFG-Kw7nIkVZ0aPi71kM0JIbnHKE3v2B7IIn3zGNwSdM5HQDzqdMbr0NG_TOkutpAE_uYHR9HwZ4cHHaCVe-nSy2pNkSIN-cD5Gcw5hcS9ac3IV-m8OI5Ao9Zmeh77ezw4Y4hgh5tq18DuQMbMbooCeXGKPLzpMb8GGEOHt6TB-Ktx30CU-e6nHx8_Lix_n1Yn17tTo_XS-sVGVedICNKktQllkUusGSVl1TyablqKERlila1UpKLCvQQsmuQla1GmutG9FwcVys9tw2wL0Zoxsgbk0AZx4PQtyYp5GM0rzGSjBKdStLLIErYS2tZV3TrmPdzPq6Z41TM2Br0e8e-hX09Y13v8wmPBitpVKsngGfnwAx_J4wZTO4ZLHvwWOYkuFSs3L-Ty5nKdtLbQwpReye2zBqdqExj6Exu9CYfWhmz6eX8z07_kdE_ANnaMS8 |
| CitedBy_id | crossref_primary_10_3390_molecules27092716 crossref_primary_10_1016_j_arcmed_2023_02_003 crossref_primary_10_3389_fimmu_2021_689187 crossref_primary_10_1038_s41541_022_00539_0 crossref_primary_10_3390_vaccines10111920 crossref_primary_10_3390_vaccines11111675 crossref_primary_10_3389_fimmu_2023_1272018 crossref_primary_10_1002_jmv_29115 crossref_primary_10_1016_j_apmt_2022_101535 crossref_primary_10_1515_mr_2023_0001 crossref_primary_10_3390_vaccines9111338 crossref_primary_10_1152_ajprenal_00130_2021 crossref_primary_10_3390_v13061091 crossref_primary_10_1016_j_immuni_2022_04_010 |
| Cites_doi | 10.1016/j.jmb.2012.12.017 10.4161/self.1.3.11897 10.3322/caac.21492 10.15570/actaapa.2018.40 10.1016/S1074-7613(03)00149-3 10.1038/s41590-019-0395-0 10.1006/viro.2000.0272 10.3390/v12010074 10.1371/journal.pone.0099881 10.1093/jnci/djaa011 10.1002/ijc.27831 10.1177/0961203309346653 10.1128/CVI.00195-13 10.1002/ijc.27675 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10.1016/j.virol.2010.10.017 10.1073/pnas.1012923107 10.1371/journal.ppat.1008827 10.1128/JVI.01088-09 10.1038/s41598-017-18177-1 10.1128/JVI.00449-16 10.1016/j.vaccine.2014.03.033 10.1039/C9NR06160F 10.1371/journal.pone.0120152 10.1038/srep12501 10.1042/CS20160786 10.1016/j.cell.2015.07.043 10.1038/nm.3927 10.1373/clinchem.2005.052381 10.1016/j.virol.2010.02.002 10.1016/j.csbj.2015.11.001 10.1016/S1470-2045(10)70230-8 10.1016/j.vaccine.2015.09.005 10.1128/JVI.01577-07 10.1128/JVI.01349-18 10.1002/ijc.31937 10.1038/srep35182 10.1016/j.virol.2005.04.011 10.1128/JVI.77.15.8386-8393.2003 10.1007/s10529-019-02755-6 10.1158/1940-6207.CAPR-15-0164 10.1038/nri3488 10.1159/000312878 10.1016/j.vaccine.2009.01.102 10.1016/j.pep.2016.04.012 10.1016/S1470-2045(12)70137-7 10.1021/ja0655690 10.1016/j.nano.2018.11.009 10.1038/nature12202 10.1038/srep04729 10.1158/1940-6207.CAPR-13-0203 10.1093/annonc/mdr015 10.1586/14760584.2014.963561 10.1128/JVI.01930-17 10.1128/CVI.00139-12 10.1038/s41565-020-0648-y 10.1038/13484 10.1016/j.peptides.2008.05.022 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 Yang, Mariz, Zhao, Spagnoli, Ottonello and Müller. Copyright © 2020 Yang, Mariz, Zhao, Spagnoli, Ottonello and Müller 2020 Yang, Mariz, Zhao, Spagnoli, Ottonello and Müller |
| Copyright_xml | – notice: Copyright © 2020 Yang, Mariz, Zhao, Spagnoli, Ottonello and Müller. – notice: Copyright © 2020 Yang, Mariz, Zhao, Spagnoli, Ottonello and Müller 2020 Yang, Mariz, Zhao, Spagnoli, Ottonello and Müller |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fimmu.2020.606569 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-3224 |
| ExternalDocumentID | oai_doaj_org_article_6729e831007d45e5a263cc094990ff1f 10_3389_fimmu_2020_606569 33343580 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CGR CUY CVF DIK EBS ECM EIF EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW IPNFZ KQ8 M48 M~E NPM OK1 PGMZT RIG RNS RPM AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c465t-faeb655a6c1ce37be508fb84bd2e7ab3c16089644e58a7364f8e18d7e977b3b23 |
| IEDL.DBID | RPM |
| ISSN | 1664-3224 |
| IngestDate | Tue Oct 22 15:08:03 EDT 2024 Tue Sep 17 21:19:18 EDT 2024 Sat Oct 26 04:31:11 EDT 2024 Thu Sep 26 17:51:45 EDT 2024 Sat Nov 02 11:56:28 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | nanoparticle ferritin neutralizing Abs thioredoxin cervical cancer human papillomavirus |
| Language | English |
| License | Copyright © 2020 Yang, Mariz, Zhao, Spagnoli, Ottonello and Müller. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c465t-faeb655a6c1ce37be508fb84bd2e7ab3c16089644e58a7364f8e18d7e977b3b23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: John Schiller, National Cancer Institute (NCI), United States; Bryce Chackerian, University of New Mexico, United States This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology Edited by: Cornelis Joseph Melief, Leiden University, Netherlands |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746619/ |
| PMID | 33343580 |
| PQID | 2471533424 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6729e831007d45e5a263cc094990ff1f pubmedcentral_primary_oai_pubmedcentral_nih_gov_7746619 proquest_miscellaneous_2471533424 crossref_primary_10_3389_fimmu_2020_606569 pubmed_primary_33343580 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-12-04 |
| PublicationDateYYYYMMDD | 2020-12-04 |
| PublicationDate_xml | – month: 12 year: 2020 text: 2020-12-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in immunology |
| PublicationTitleAlternate | Front Immunol |
| PublicationYear | 2020 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Bray (B9) 2018; 68 Pouyanfard (B25) 2018; 92 Zhao (B50) 2020; 16 Qu (B42) 2020; 42 Neirynck (B51) 1999; 5 Smith (B26) 2013; 13 Rubio (B12) 2011; 409 Kanekiyo (B29) 2013; 499 Rubio (B21) 2009; 27 Seitz (B13) 2015; 8 Arbyn (B1) 2011; 22 Chackerian (B28) 2020; 12 Huber (B8) 2015; 10 Lee (B54) 2016; 6 Eiselt (B44) 2010; 115 Agmon-Levin (B58) 2009; 18 Pastrana (B14) 2005; 337 Wang (B36) 2019; 16 Schellenbacher (B17) 2009; 83 Sterbenc (B52) 2018; 27 Jagu (B10) 2015; 33 Castro (B39) 2013; 132 Varsani (B16) 2003; 77 Seitz (B19) 2013; 20 Kanekiyo (B49) 2015; 162 Brodeur (B59) 2003; 18 Spagnoli (B24) 2017; 7 Kanekiyo (B34) 2019; 20 Kanduc (B57) 2008; 29 Boxus (B18) 2016; 90 Zhou (B33) 2014; 9 Day (B38) 2012; 19 de Martel (B6) 2012; 13 McLellan (B46) 2013; 123 He (B31) 2015; 5 Seitz (B20) 2014; 32 Gambhira (B11) 2007; 81 Graham (B2) 2017; 131 Wang (B47) 2020; 15 Kwon (B48) 2019; 11 Darricarrere (B35) 2018; 92 Kreimer (B55) 2020; 112 Ferlay (B3) 2019; 144 Safaeian (B45) 2013; 6 Seitz (B37) 2013; 132 de Sanjose (B5) 2010; 11 Bernard (B7) 2010; 401 Hofmeyer (B43) 2013; 425 Waterboer (B40) 2005; 51 Burton (B32) 2010; 107 Lopez-Sagaseta (B27) 2016; 14 Walboomers (B4) 1999; 189 Yassine (B30) 2015; 21 Uchida (B41) 2006; 128 Kanduc (B56) 2010; 1 Spagnoli (B22) 2017; 129 Roden (B15) 2000; 270 Canali (B23) 2014; 4 Chatterjee (B53) 2014; 13 |
| References_xml | – volume: 425 year: 2013 ident: B43 article-title: Arranged Sevenfold: Structural Insights into the C-Terminal Oligomerization Domain of Human C4b-Binding Protein publication-title: J Mol Biol doi: 10.1016/j.jmb.2012.12.017 contributor: fullname: Hofmeyer – volume: 1 year: 2010 ident: B56 article-title: The self/nonself issue: A confrontation between proteomes publication-title: Self Nonself doi: 10.4161/self.1.3.11897 contributor: fullname: Kanduc – volume: 68 start-page: 394 year: 2018 ident: B9 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA: Cancer J Clin doi: 10.3322/caac.21492 contributor: fullname: Bray – volume: 27 start-page: 193 year: 2018 ident: B52 article-title: Recent advances in prophylactic human papillomavirus (HPV) vaccination: a review of key literature published between September 2017 and September 2018 publication-title: Acta Dermatovenerol Alp Pannonica Adriat doi: 10.15570/actaapa.2018.40 contributor: fullname: Sterbenc – volume: 18 year: 2003 ident: B59 article-title: C4b-binding protein (C4BP) activates B cells through the CD40 receptor publication-title: Immunity doi: 10.1016/S1074-7613(03)00149-3 contributor: fullname: Brodeur – volume: 20 year: 2019 ident: B34 article-title: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses (vol 20, pg 362, 2019) publication-title: Nat Immunol doi: 10.1038/s41590-019-0395-0 contributor: fullname: Kanekiyo – volume: 270 year: 2000 ident: B15 article-title: Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes publication-title: Virology doi: 10.1006/viro.2000.0272 contributor: fullname: Roden – volume: 12 start-page: 1 year: 2020 ident: B28 article-title: Factors That Govern the Induction of Long-Lived Antibody Responses publication-title: Viruses-Basel doi: 10.3390/v12010074 contributor: fullname: Chackerian – volume: 9 start-page: 1 year: 2014 ident: B33 article-title: Transplanting Supersites of HIV-1 Vulnerability publication-title: PloS One doi: 10.1371/journal.pone.0099881 contributor: fullname: Zhou – volume: 112 year: 2020 ident: B55 article-title: Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial publication-title: J Natl Cancer Institute doi: 10.1093/jnci/djaa011 contributor: fullname: Kreimer – volume: 132 year: 2013 ident: B37 article-title: Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2 publication-title: Int J Cancer doi: 10.1002/ijc.27831 contributor: fullname: Seitz – volume: 18 year: 2009 ident: B58 article-title: Molecular mimicry in systemic lupus erythematosus publication-title: Lupus doi: 10.1177/0961203309346653 contributor: fullname: Agmon-Levin – volume: 20 year: 2013 ident: B19 article-title: Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-l2 prophylactic papillomavirus vaccine publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00195-13 contributor: fullname: Seitz – volume: 132 year: 2013 ident: B39 article-title: High-throughput SNP-based authentication of human cell lines publication-title: Int J Cancer doi: 10.1002/ijc.27675 contributor: fullname: Castro – volume: 189 year: 1999 ident: B4 article-title: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide publication-title: J Pathol doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F contributor: fullname: Walboomers – volume: 409 year: 2011 ident: B12 article-title: The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies publication-title: Virology doi: 10.1016/j.virol.2010.10.017 contributor: fullname: Rubio – volume: 107 year: 2010 ident: B32 article-title: Scaffolding to build a rational vaccine design strategy publication-title: P Natl Acad Sci USA doi: 10.1073/pnas.1012923107 contributor: fullname: Burton – volume: 16 start-page: e1008827 year: 2020 ident: B50 article-title: Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine publication-title: PloS Pathog doi: 10.1371/journal.ppat.1008827 contributor: fullname: Zhao – volume: 83 year: 2009 ident: B17 article-title: Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines publication-title: J Virol doi: 10.1128/JVI.01088-09 contributor: fullname: Schellenbacher – volume: 7 start-page: 18000 year: 2017 ident: B24 article-title: Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles publication-title: Sci Rep doi: 10.1038/s41598-017-18177-1 contributor: fullname: Spagnoli – volume: 90 year: 2016 ident: B18 article-title: Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles publication-title: J Virol doi: 10.1128/JVI.00449-16 contributor: fullname: Boxus – volume: 32 year: 2014 ident: B20 article-title: A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses publication-title: Vaccine doi: 10.1016/j.vaccine.2014.03.033 contributor: fullname: Seitz – volume: 11 year: 2019 ident: B48 article-title: Viral antigen nanoparticles for discriminated and quantitative detection of different subtypes of anti-virus immunoglobulins publication-title: Nanoscale doi: 10.1039/C9NR06160F contributor: fullname: Kwon – volume: 10 start-page: e0120152 year: 2015 ident: B8 article-title: A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types publication-title: PloS One doi: 10.1371/journal.pone.0120152 contributor: fullname: Huber – volume: 5 start-page: 1 year: 2015 ident: B31 article-title: Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding publication-title: Sci Rep Uk doi: 10.1038/srep12501 contributor: fullname: He – volume: 131 year: 2017 ident: B2 article-title: The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review publication-title: Clin Sci (Lond) doi: 10.1042/CS20160786 contributor: fullname: Graham – volume: 162 year: 2015 ident: B49 article-title: Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site publication-title: Cell doi: 10.1016/j.cell.2015.07.043 contributor: fullname: Kanekiyo – volume: 123 start-page: 3 year: 2013 ident: B46 article-title: Mid Staffordshire inquiry. Too long, too late but Francis can still help make the NHS better publication-title: Health Serv J contributor: fullname: McLellan – volume: 21 year: 2015 ident: B30 article-title: Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection publication-title: Nat Med doi: 10.1038/nm.3927 contributor: fullname: Yassine – volume: 51 year: 2005 ident: B40 article-title: Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins publication-title: Clin Chem doi: 10.1373/clinchem.2005.052381 contributor: fullname: Waterboer – volume: 401 year: 2010 ident: B7 article-title: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments publication-title: Virology doi: 10.1016/j.virol.2010.02.002 contributor: fullname: Bernard – volume: 14 start-page: 58 year: 2016 ident: B27 article-title: Self-assembling protein nanoparticles in the design of vaccines publication-title: Comput Struct Biotechnol J doi: 10.1016/j.csbj.2015.11.001 contributor: fullname: Lopez-Sagaseta – volume: 11 year: 2010 ident: B5 article-title: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70230-8 contributor: fullname: de Sanjose – volume: 33 year: 2015 ident: B10 article-title: Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes publication-title: Vaccine doi: 10.1016/j.vaccine.2015.09.005 contributor: fullname: Jagu – volume: 81 year: 2007 ident: B11 article-title: Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2 publication-title: J Virol doi: 10.1128/JVI.01577-07 contributor: fullname: Gambhira – volume: 92 year: 2018 ident: B35 article-title: Development of a Pan-H1 Influenza Vaccine publication-title: J Virol doi: 10.1128/JVI.01349-18 contributor: fullname: Darricarrere – volume: 144 year: 2019 ident: B3 article-title: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods publication-title: Int J Cancer doi: 10.1002/ijc.31937 contributor: fullname: Ferlay – volume: 6 start-page: 35182 year: 2016 ident: B54 article-title: Engineered Human Ferritin Nanoparticles for Direct Delivery of Tumor Antigens to Lymph Node and Cancer Immunotherapy publication-title: Sci Rep doi: 10.1038/srep35182 contributor: fullname: Lee – volume: 337 year: 2005 ident: B14 article-title: Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2 publication-title: Virology doi: 10.1016/j.virol.2005.04.011 contributor: fullname: Pastrana – volume: 77 year: 2003 ident: B16 article-title: Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16 publication-title: J Virol doi: 10.1128/JVI.77.15.8386-8393.2003 contributor: fullname: Varsani – volume: 42 start-page: 57 year: 2020 ident: B42 article-title: Expression, purification, and characterisation of recombinant ferritin in insect cells using the baculovirus expression system publication-title: Biotechnol Lett doi: 10.1007/s10529-019-02755-6 contributor: fullname: Qu – volume: 8 year: 2015 ident: B13 article-title: Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine publication-title: Cancer Prev Res (Phila) doi: 10.1158/1940-6207.CAPR-15-0164 contributor: fullname: Seitz – volume: 13 start-page: 592 year: 2013 ident: B26 article-title: Applications of nanotechnology for immunology publication-title: Nat Rev Immunol doi: 10.1038/nri3488 contributor: fullname: Smith – volume: 115 year: 2010 ident: B44 article-title: High ferritin, but not hepcidin, is associated with a poor immune response to an influenza vaccine in hemodialysis patients publication-title: Nephron Clin Pract doi: 10.1159/000312878 contributor: fullname: Eiselt – volume: 27 year: 2009 ident: B21 article-title: Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 – 38) peptide displayed on bacterial thioredoxin publication-title: Vaccine doi: 10.1016/j.vaccine.2009.01.102 contributor: fullname: Rubio – volume: 129 year: 2017 ident: B22 article-title: Secretory production of designed multipeptides displayed on a thermostable bacterial thioredoxin scaffold in Pichia pastoris publication-title: Protein Expr Purif doi: 10.1016/j.pep.2016.04.012 contributor: fullname: Spagnoli – volume: 13 year: 2012 ident: B6 article-title: Global burden of cancers attributable to infections in 2008: a review and synthetic analysis publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70137-7 contributor: fullname: de Martel – volume: 128 year: 2006 ident: B41 article-title: Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles publication-title: J Am Chem Soc doi: 10.1021/ja0655690 contributor: fullname: Uchida – volume: 16 start-page: 69 year: 2019 ident: B36 article-title: Ferritin nanoparticle-based SpyTag/SpyCatcher-enabled click vaccine for tumor immunotherapy publication-title: Nanomed-Nanotechnol doi: 10.1016/j.nano.2018.11.009 contributor: fullname: Wang – volume: 499 year: 2013 ident: B29 article-title: Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies publication-title: Nature doi: 10.1038/nature12202 contributor: fullname: Kanekiyo – volume: 4 start-page: 4729 year: 2014 ident: B23 article-title: A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope publication-title: Sci Rep doi: 10.1038/srep04729 contributor: fullname: Canali – volume: 6 year: 2013 ident: B45 article-title: Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial publication-title: Cancer Prev Res (Phila) doi: 10.1158/1940-6207.CAPR-13-0203 contributor: fullname: Safaeian – volume: 22 year: 2011 ident: B1 article-title: Worldwide burden of cervical cancer in 2008 publication-title: Ann Oncol doi: 10.1093/annonc/mdr015 contributor: fullname: Arbyn – volume: 13 year: 2014 ident: B53 article-title: The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon publication-title: Expert Rev Vaccines doi: 10.1586/14760584.2014.963561 contributor: fullname: Chatterjee – volume: 92 start-page: e01930–17 year: 2018 ident: B25 article-title: Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses publication-title: J Virol doi: 10.1128/JVI.01930-17 contributor: fullname: Pouyanfard – volume: 19 year: 2012 ident: B38 article-title: A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies publication-title: Clin Vaccine Immunol CVI doi: 10.1128/CVI.00139-12 contributor: fullname: Day – volume: 15 year: 2020 ident: B47 article-title: Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B publication-title: Nat Nanotechnol doi: 10.1038/s41565-020-0648-y contributor: fullname: Wang – volume: 5 year: 1999 ident: B51 article-title: A universal influenza A vaccine based on the extracellular domain of the M2 protein publication-title: Nat Med doi: 10.1038/13484 contributor: fullname: Neirynck – volume: 29 year: 2008 ident: B57 article-title: Massive peptide sharing between viral and human proteomes publication-title: Peptides doi: 10.1016/j.peptides.2008.05.022 contributor: fullname: Kanduc |
| SSID | ssj0000493335 |
| Score | 2.3842254 |
| Snippet | Cervical cancer remains a global health burden despite the introduction of highly effective vaccines for the prophylaxis of causative human papillomavirus... |
| SourceID | doaj pubmedcentral proquest crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 606569 |
| SubjectTerms | Alphapapillomavirus - drug effects Alphapapillomavirus - genetics Alphapapillomavirus - immunology Animals Antibodies, Viral - blood Antibody Specificity Bacterial Proteins - genetics Bacterial Proteins - immunology Bacterial Proteins - pharmacology Broadly Neutralizing Antibodies - blood Capsid Proteins - genetics Capsid Proteins - immunology Capsid Proteins - pharmacology cervical cancer Epitopes Female ferritin Ferritins - genetics Ferritins - immunology Ferritins - pharmacology Guinea Pigs human papillomavirus Immunization Immunogenicity, Vaccine Immunology Mice, Inbred BALB C nanoparticle Nanoparticles neutralizing Abs Oncogene Proteins, Viral - genetics Oncogene Proteins, Viral - immunology Oncogene Proteins, Viral - pharmacology Papillomavirus Infections - blood Papillomavirus Infections - immunology Papillomavirus Infections - prevention & control Papillomavirus Vaccines - genetics Papillomavirus Vaccines - immunology Papillomavirus Vaccines - pharmacology Sf9 Cells Spodoptera thioredoxin Thioredoxins - genetics Thioredoxins - immunology Thioredoxins - pharmacology Time Factors Vaccines, DNA - pharmacology |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9QwFA6yIPgi3h1vRPBJqNvm3sfdxWEVd13EhX0ruWplph1mWmH-kz_Sk6S7zIjgi69tQk9zTnK-k5x8B6E3YLeck9oWuiKhYJULhSHCFEzL2nrlRCjj3eGzc3F6yT5e8audUl8xJyzTA-eBOxSA_nyshlVKx7jnmghqbRk5VcoQqpBW37LeCaZ-ZNxLKeX5GBOisPowtMvlCPEgKd8BZucxwXnHESW-_r-BzD9zJXecz_weujuhRnyUpb2PbvnuAbqd60huH6JfEExrh8_9mPYt8s1K_CWnv_oNPvoG8f9mwJ8724PBtBanvXt8oVftYtEv9c92PcaGsZCH9Q6bLdb4rO36NT7RKzBY_Ingi36xHfqVx5GqOm2BL7bQw05cyNDtQzf0-DjzP4O488j6OLQdhiUcYvMpBe8Rupy__3pyWkxlGArLBB-KoL0RnGthK-upNB4wXTCKGUe81IbaSpSqBlzludKSChaUr5STHqCloYbQx-ig6zv_FGFwfk6B2pyWiimrDams4s6aWjpOmZyht9c6aVaZbaOBKCUqsEkKbKICm6zAGTqOWrtpGImy0wMwn2b6p-Zf5jNDr6913sDEiqcluvP9uGkIuO14T5mwGXqSbeDmU2BbLJ4fz5Dcs449WfbfdO33RN4NcBsgUf3sfwj_HN2J45Gya9gLdDCsR_8SMNJgXqXp8BtOOBPP priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKEaiXimdJechInJBSEseP5IBQW7EqiJYKsVJvkV8pQdlkySaI_Cd-JOM4W7FoT1w3tuL1jDPfZ4-_QegV-C1jJNOhjEkR0tgUoSJchVSKTNvU8CJyd4fPL_jZnH68Ylc7aF3eaprA1VZq5-pJzdvq6NeP4R0s-LeOcUK8fVOUi0UPVI9ERwDHGc9uoduEAlF3mXwT2v_uwXCSJMyfbW7vuYfuQhPqzgY3AtWo578NhP6bS_lXcJrdQ_sTqsTH3g3uox1bP0B3fJ3J4SH6DWRbGnxh-3Ffw9-8xF98eqxd4eNrWQJMxJ9r3YBDlRqPe_v4Ui7LqmoW8mfZ9q6hK_ShrcFqwBKfl3XT4lO5BIfGnwi-bKqhg9nDTsp63CKvBuihJ61k6Pah7hp84vWhYbgzpwrZlTWGTzxw9ylF7xGaz95_PT0LpzINoaacdWEhreKMSa5jbROhLGC-QqVUGWKFVImOeZRmgLssS6VIOC1SG6dGWICeKlEkeYx266a2TxCG4GjSqCiMFClNtVQk1ikzWmXCsISKAL1e2yRfejWOHFiMs2U-2jJ3tsy9LQN04qx209AJaY8_NO11Pv2nnAO5sK7YWiQMZZZJwhOtIyfZA-OIiwC9XNs8h4XnTlNkbZt-lRMI6-4eM6EBOvA-cPOqtQ8FSGx4x8ZYNp_U5bdR3BvgOECm7PC_ez5Fe24SxpQb-gztdm1vnwNw6tSLcTn8AdGpHYA priority: 102 providerName: Scholars Portal |
| Title | Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33343580 https://www.proquest.com/docview/2471533424 https://pubmed.ncbi.nlm.nih.gov/PMC7746619 https://doaj.org/article/6729e831007d45e5a263cc094990ff1f |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LatwwFBVJoNBN6bvuI6jQVcEztizJ8jIZOk1LJx1KA7Mzejl1GT-Y2IX5p35kr2Q7ZEpX3XhhS1jWPfI9V7o6Qugd4JYxkulQxqQIaWyKUBGuQirTTFtheBG5vcOrS35xRT9v2OYIsWkvjE_a16qc1dtqVpc_fG5lW-n5lCc2X68WQFnArWTzY3QMAL0Tov8cKG-SJGxYwYQALJsXZVX1EAqSaAZ0nXGnFApFqFsBPHBHXrX_X1Tz74zJOy5o-RA9GLkjPhva-Agd2foxujecJrl_gn5DSC0NvrS9n70Y9lfib0MSrL3BZ9eyBDKIv9a6AdiUGvsZfLyWbbndNpX8Ve56V9Ad56GtwWqPJV6VdbPDC9kCbPEXgtfNdt81rcVOsNpPhG_3UEOPishQ7VPdNfh8UIGG5i6d9mNX1hh-5BChjx38FF0tP3xfXITjYQyhppx1YSGt4oxJrmNtk1RZYHaFElQZYlOpEh3zSGTAriwTMk04LYSNhUktEEyVKJI8Qyd1U9sXCIMLNCIqCiNTQYWWisRaMKNVlhqW0DRA7yeb5O2guZFDrOJsmXtb5s6W-WDLAJ07q90WdHLZ_kazu87Hb8o5hBDWHakWpYYyyyThidaRE-aBdsRFgN5ONs9heLk1E1nbpr_JCThvt1uZ0AA9HzBw-6oJQwFKD9Bx0JbDJ4BoL-E9Ivjlf9d8he67TvCJNfQ1Oul2vX0D9KhTp35aAa4fNzFcV1Sc-gHyB0TaGAM |
| link.rule.ids | 230,315,730,783,787,867,888,2109,24330,27936,27937,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGEIIX7pdyNRJPSGkTx3aSx62i2qAtFdrQ3iLfMgJtUnUJUvlN_EiO7WRaJ17gNbYVO_mOznfs4-8g9A5wyxjJVCAiUgQ00kUgCZcBFUmmTKp5Edq7w7M5PzqlH8_Y2R5i_V0Yl7SvZDmslqthVX5zuZXrlRr1eWKjxWwMlAXcSja6gW6CvYb0SpD-3ZPeOI6ZP8OEECwbFeVq1UIwSMIhEHbGrVYodKH2DHDHITnd_r-Rzes5k1ec0OQe-tpP3-ee_Bi2jRyqX9eUHf95fffR3Y6W4gPf_ADtmeohuuULVW4fod8QrQuN56Z1GyP-6ib-4vNrzQU-OBcl8Ez8uVI1ILJU2B0O4IVYl8tlvRI_y01rO9pKIcpoLLdY4FlZ1Rs8FmuwCDwleFEvt029NthqYbs99uUWRqhObBmGHVdNjQ-9wDRMd2JlJZuywuAjIPjv1vYYnU4-nIyPgq7OQ6AoZ01QCCM5Y4KrSJk4kQZIYyFTKjUxiZCxiniYZkDcDEtFEnNapCZKdWKAu8pYkvgJ2q_qyjxDGLyrTsOi0CJJaaqEJJFKmVYySzSLaTJA7_ufna-9nEcOYZAFSe5AkluQ5B4kA3Ro4XDZ0Spxuwf15jzv1pRziE6MrdYWJpoywwThsVKh1fyBeUTFAL3twZSD5drjGFGZur3ICfACexGa0AF66sF1-aoenAOU7MBuZy67LQAmpw7egef5f498g24fncym-fR4_ukFumM_iMvfoS_RfrNpzStgYY187WzuDxx2N0E |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgCMQL90G5GoknpLSJYzvJ41aoNlhLhZg08RL5OgJtEnUJUvlN_EiO42ZqJ572mhwrPslnne_Ex99B6B3gljGSqUBExAY00jaQhMuAiiRTJtXchu7s8HTGj07ppzN2ttXqqyvaV7IYlovlsCx-dLWV9VKN-jqx0Xw6BsoCYSUb1dqObqJbsGZDvpWo__TEN45j5vcxIQ3LRrZYLltICEk4BNLOuNMLBRPq9gF3glKn3f8_wnm1bnIrEE3uo--9C77-5NewbeRQ_bmi7ngtHx-gext6ig-8yUN0w5SP0G3fsHL9GP2FrF1oPDNt94PEH-HEX32drbnAB-eiAL6Jv5SqAmQWCnebBHgu6mKxqJbid7FqnaHrGKKMxnKNBZ4WZbXCY1HDysAnBM-rxbqpaoOdJnb3r32xhhFqI7oMw47LpsKHXmgapjtx8pJNUWKIFVXd-_cEnU4-fhsfBZt-D4GinDWBFUZyxgRXkTJxIg2QRytTKjUxiZCxiniYZkDgDEtFEnNqUxOlOjHAYWUsSbyP9sqqNM8Qhiir09BaLZKUpkpIEqmUaSWzRLOYJgP0vv_gee1lPXJIhxxQ8g4ouQNK7oEyQIcOEpeGTpG7u1CtzvONTzmHLMW4rm1hoikzTBAeKxU67R-YR2QH6G0PqBxWsNuWEaWp2oucAD9wB6IJHaCnHmCXj-oBOkDJDvR25rJ7BwDVqYRvAPT82iPfoDvzD5P85Hj2-QW6695HV8ZDX6K9ZtWaV0DGGvm6W3b_AKL6OcE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Broad+Neutralization+Responses+Against+Oncogenic+Human+Papillomaviruses+Induced+by+a+Minor+Capsid+L2+Polytope+Genetically+Incorporated+Into+Bacterial+Ferritin+Nanoparticles&rft.jtitle=Frontiers+in+immunology&rft.au=Yang%2C+Fan&rft.au=Mariz%2C+Filipe+C.&rft.au=Zhao%2C+Xueer&rft.au=Spagnoli%2C+Gloria&rft.date=2020-12-04&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=11&rft_id=info:doi/10.3389%2Ffimmu.2020.606569&rft_id=info%3Apmid%2F33343580&rft.externalDBID=PMC7746619 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |